secwatch.observer — SEC 8-K summary
======================================

Issuer:     Forte Biosciences, Inc. (FBRX)
CIK:        0001419041
Form:       8-K
Filed at:   2024-06-14T23:59:59+00:00
Accession:  0001193125-24-161592
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Forte settles shareholder suit; board expands to 9, Camac appoints 2 directors, poison pill expires July 2024
--------------------------------------------------------------------------------

- Board expands to nine seats; one incumbent director resigns; two Camac-selected directors appointed from five-company-identified candidates.
- Strategic alternatives committee formed including Camac nominees; rights plan expires July 12, 2024, not renewed, no new plan for 3 years.
- Camac enters standstill/voting agreement through 2028; company pays $364k for Camac's 2023 proxy contest out-of-pocket expenses.
- Settlement resolves claims that July 2023 private placement (~$25M) was intended to entrench board and block Camac director nominees.
- The standstill prohibits Camac from acquiring additional shares, launching proxy contests, or seeking board representation until 2028.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1419041/000119312524161592/0001193125-24-161592-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1419041/000119312524161592/d826178d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-161592

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer